Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
3 No-Brainer Stocks to Buy Right Now for Less Than $6
10:55am, Saturday, 26'th Mar 2022 The Motley Fool
These stocks are all about cutting-edge technology.
Is It Too Late to Buy Vaxart Stock?
03:37pm, Thursday, 24'th Mar 2022 The Motley Fool
The past 12 months have been difficult for the biotech stock.
Is It Too Late to Buy Vaxart Stock?
11:37am, Thursday, 24'th Mar 2022
The past 12 months have been difficult for the biotech stock.
Can Vaxart Inc. (NASDAQ: VXRT) Still Be Considered A Loss When It’s Down -24.08% YTD?
01:30pm, Thursday, 10'th Mar 2022 Marketing Sentinel
During the last session, Vaxart Inc. (NASDAQ:VXRT)’s traded shares were 3.06 million, with the beta value of the company hitting 0.45. At the end of the trading day, the stock’s price was $4.76, reflecting an intraday gain of 8.68% or $0.38. The 52-week high for the VXRT share is $11.11, that puts it down -133.4 … Can Vaxart Inc. (NASDAQ: VXRT) Still Be Considered A Loss When It’s Down -24.08% YTD? Read More »
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
11:30am, Wednesday, 09'th Mar 2022 The Motley Fool
Vaxart is winning in two crucial areas.
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
11:30am, Wednesday, 09'th Mar 2022 The Motley Fool
Vaxart is winning in two crucial areas.
These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals
06:30am, Wednesday, 09'th Mar 2022
Vaxart is winning in two crucial areas.
Vaxart Stock: Awaiting Platform Validation for the Bull-Case to Kick In
07:34pm, Monday, 07'th Mar 2022 TipRanksVaxart (VXRT) shot to prominence in the early days of the pandemic, as one of the small vaccine makers taking the fight to Covid-19. But that was a while ago
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
08:24am, Saturday, 26'th Feb 2022 Seeking AlphaVaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
03:24am, Saturday, 26'th Feb 2022
Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022.
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
12:10am, Friday, 25'th Feb 2022 Zacks Investment Research
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vaxart GAAP EPS of -$0.17 misses by $0.01, revenue of $0.07M misses by $0.11M
10:30pm, Thursday, 24'th Feb 2022 Seeking Alpha
Vaxart press release (NASDAQ:VXRT): Q4 GAAP EPS of -$0.17 misses by $0.01.Revenue of $0.07M (-80.6% Y/Y) misses by $0.11M.
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
09:05pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
Company begins 2022 with multiple active programs with data readouts expected this year
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
08:46pm, Thursday, 24'th Feb 2022
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021.
Vaxart shares fall following data on COVID vaccine
02:20pm, Thursday, 24'th Feb 2022 Seeking Alpha
Shares of Vaxart (VXRT) are down 10% in premarket trading after releasing mid-stage data on its oral COVID-19 vaccine candidate.
